Abstract: Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

Abstract: Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

Abstract: Disclosed herein is a formulation for mitigating brain trauma including, in some embodiments, one or more ?-3 fatty acids, one or more curcuminoids, trans-resveratrol, ?-glycerylphosphorylcholine (“?-GPC”), and uridine-5?-monophosphate (“UMP”). The formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration. Also disclosed herein is a packaged formulation for mitigating brain trauma including, in some embodiments, a sealed pouch containing a single dose of the oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, trans-resveratrol, ?-GPC, and UMP.

Abstract: Disclosed herein is a formulation for mitigating brain trauma including, in some embodiments, one or more ?-3 fatty acids, one or more curcuminoids, trans-resveratrol, ?-glycerylphosphorylcholine (“?-GPC”), and uridine-5?-monophosphate (“UMP”). The formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration. Also disclosed herein is a packaged formulation for mitigating brain trauma including, in some embodiments, a sealed pouch containing a single dose of the oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, trans-resveratrol, ?-GPC, and UMP.

Abstract: Disclosed herein is a formulation for mitigating brain trauma including, in some embodiments, one or more ?-3 fatty acids, one or more curcuminoids, trans-resveratrol, ?-glycerylphosphorylcholine (“?-GPC”), and uridine-5?-monophosphate (“UMP”). The formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration. Also disclosed herein is a packaged formulation for mitigating brain trauma including, in some embodiments, a sealed pouch containing a single dose of the oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, trans-resveratrol, ?-GPC, and UMP.

Abstract: Disclosed herein is a formulation for mitigating brain trauma including, in some embodiments, one or more ?-3 fatty acids, one or more curcuminoids, trans-resveratrol, ?-glycerylphosphorylcholine (“?-GPC”), and uridine-5?-monophosphate (“UMP”). The formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration. Also disclosed herein is a packaged formulation for mitigating brain trauma including, in some embodiments, a sealed pouch containing a single dose of the oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, trans-resveratrol, ?-GPC, and UMP.

Abstract: A method for mitigating the effects of traumatic brain injury in an individual comprising is disclosed. The method includes administering an amount of a composition prior to a period wherein the traumatic brain injury is expected to occur, wherein the composition is comprised of: 300 mg and 500 milligrams (mg) of Docosahexaenoic acid (DHA), 50 mg/kg to 400 mg/kg (milligrams of composition per kilogram of body weight of the individual) of curcumin, and 10 mg to 100 mg of resveratrol. In some embodiments, the composition may include 350 mg of DHA, 150 mg/kg of curcumin and 30 mg of resveratrol, In additional embodiments, the composition may further include ?-linoleic acid of an amount within the range of, for example, 1-2 g. The composition may be administered to the individual within a predetermined amount of time prior to a period wherein the traumatic brain injury is expected to occur.

Abstract: A method for mitigating the effects of traumatic brain injury in an individual comprising is disclosed. The method includes administering an amount of a composition prior to a period wherein the traumatic brain injury is expected to occur, wherein the composition is comprised of: 300 mg and 500 milligrams (mg) of Docosahexaenoic acid (DHA), 50 mg/kg to 400 mg/kg (milligrams of composition per kilogram of body weight of the individual) of curcumin, and 10 mg to 100 mg of resveratrol. In some embodiments, the composition may include 350 mg of DHA, 150 mg/kg of curcumin and 30 mg of resveratrol. In additional embodiments, the composition may further include ?-linoleic acid of an amount within the range of, for example, 1-2 g. The composition may be administered to the individual within a predetermined amount of time prior to a period wherein the traumatic brain injury is expected to occur.

Abstract: Compositions and methods and provided for preventing or mitigating the effects of traumatic brain injuries, such as concussions. The compositions comprises between 100-11500 mg Docosahexaenoic acid (DHA), 100-3000 mg curcumin, and 100-3000 mg of resveratrol. The compositions may further include 100-3000 mg of ?-linoleic acid. In some embodiments, the compositions may be administered to a subject prior to, during, or after a period of time wherein a traumatic brain injury may occur or may have occurred.